Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM2 | P08172 | 7/20 | 1.00 |
| ▸ | BLM | P54132 | 4/20 | 0.97 |
| ▸ | PABPC1 | P11940 | 2/20 | 0.97 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.89 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.82 |
| ▸ | CHRM1 | P11229 | 6/20 | 0.80 |
| ▸ | CHRM5 | P08912 | 5/20 | 0.80 |
| ▸ | CHRM3 | P20309 | 5/20 | 0.80 |
| ▸ | CHRM4 | P08173 | 4/20 | 0.80 |
| ▸ | MEN1 | O00255 | 3/20 | 0.80 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.80 |
| ▸ | TSHR | P16473 | 2/20 | 0.80 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.72 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.72 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.72 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.72 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.67 |
| ▸ | LMNA | P02545 | 1/20 | 0.67 |
| ▸ | POLB | P06746 | 1/20 | 0.67 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.67 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Methylatropine SCHEMBL824874 | 1.00 | CHRM2 (1.00) | CHRM2BLMPABPC1SMN1; SMN2CYP2C19 | |
| Methylatropine SCHEMBL1321572 | 0.99 | BLM (1.00) | CHRM2BLMPABPC1SMN1; SMN2CYP2C19 | |
| Methylatropine SCHEMBL30647266 | 0.99 | BLM (1.00) | CHRM2BLMPABPC1SMN1; SMN2CYP2C19 | |
| Methylatropine SCHEMBL29389879 | 0.99 | PABPC1 (1.00) | CHRM2BLMPABPC1SMN1; SMN2CYP2C19 | |
| Methylatropine SCHEMBL30003811 | 0.94 | SMN1; SMN2 (1.00) | CHRM2BLMPABPC1SMN1; SMN2CYP2C19 | |
| Methylatropine SCHEMBL20798247 | 0.94 | SMN1; SMN2 (1.00) | CHRM2BLMPABPC1SMN1; SMN2CYP2C19 | |
| Methylatropine SCHEMBL56394 | 0.94 | SMN1; SMN2 (1.00) | CHRM2BLMPABPC1SMN1; SMN2CYP2C19 | |
| Atropine Oxide SCHEMBL98985 | 0.90 | CYP2C19 (1.00) | CHRM2BLMPABPC1SMN1; SMN2CYP2C19 | |
| Atropine Oxide SCHEMBL29369999 | 0.90 | CYP2C19 (1.00) | CHRM2BLMPABPC1SMN1; SMN2CYP2C19 | |
| Atropine Oxide SCHEMBL162929 | 0.90 | CYP2C19 (1.00) | CHRM2BLMPABPC1SMN1; SMN2CYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260102381-A1 | Muscarinic Agent Combinations | Syremis Therapeutics, Ltd. (IL) | 2026-04-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260102381-A1 | Muscarinic Agent Combinations | CHRM1, CHRM4, CHRM2 | CHRM2 3/4885BLM 2334/4885PABPC1 4792/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.